1
|
Moon SH, Sangha A, Ravichandran M, Samuela AV, Tso S, Sharma D, Ariyawardana A. Use of Lip Protecting Agents in the Prevention of Actinic Cheilitis, Herpes Labialis and Cancer of Lip: A Systematic Review. Open Dent J 2021. [DOI: 10.2174/1874210602115010428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Background:
Actinic cheilitis, herpes labialis and lip cancer are relatively common conditions presenting on the lips associated with exposure to periods of sun exposure and thereby ultraviolet radiation.
Objective:
This systematic review aimed to determine the efficacy of the application of sunscreen-containing lip-protecting agents (LPA) in the prevention of actinic cheilitis (AC), recurrent herpes labialis (RHL) and lip cancer (LC).
Methods:
This review was conducted in accordance with the PRISMA guidelines and registered with the PROSPERO database. A literature search was conducted using SCOPUS, Google Scholar, Medline (Ovid), Pubmed, CINAHL, Cochrane Library databases and manual search using search terms actinic cheilitis (AC), recurrent herpes labialis (RHL) and lip cancer (LC) along with lip protecting agents and their variations as keywords. A total of 1,567 papers were yielded. Of them, nine studies were eligible for qualitative data synthesis.
Results:
Nine articles (3 AC, 5 RHL, 1 LC) were deemed eligible and thus selected for qualitative synthesis. Three studies on AC identified approximately 21.7% lower prevalence of lesions when some form of lip protection was used. Eighty percent of studies on RHL identified that the application of LPA is effective in preventing RHL. Subjects who applied LPA more than once daily only had half the risk of having LC compared to those who applied once daily.
Conclusion:
This review of randomised controlled trials (RCTs) and observational studies supports the use of LPA as an effective method in preventing lip-associated lesions. Further, RCTs and observational studies should aim at determining a definitive LPA application regime and optimal SPF strength to prevent lip-associated lesions.
This systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO): Registration Number - CRD42020177484. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020177484
Collapse
|
2
|
Treatment Options and Post-Treatment Malignant Transformation Rate of Actinic Cheilitis: A Systematic Review. Cancers (Basel) 2021; 13:cancers13133354. [PMID: 34283099 PMCID: PMC8268797 DOI: 10.3390/cancers13133354] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2021] [Revised: 07/01/2021] [Accepted: 07/02/2021] [Indexed: 01/15/2023] Open
Abstract
Simple Summary Actinic cheilitis is a precancerous condition that may evolve to a more aggressive type of skin cancer. Therefore, its therapy is crucial for the disease prognosis. In this systematic review, we tried to identify the best therapies of actinic cheilitis regarding safety, efficacy, recurrences, and the potential to progress to skin cancer. The therapeutic approach comprised invasive and topical treatments. The invasive therapies, such as partial surgery and laser treatments, had the best cosmetic and therapeutic results with few recurrences. Photodynamic therapy demonstrated satisfactory outcomes, while topical treatments were the least beneficial. Notably, the efficacy of photodynamic therapy was improved when combined with 5% imiquimod. However, except from photodynamic therapy, the other modalities were assessed in a limited number of patients. Finally, when actinic cheilitis is treated, no risk of cancer progression exists. Larger studies are necessary to confirm these results. Abstract Actinic cheilitis is a premalignant condition that may evolve to squamous cell carcinoma. A consensus on its management has not been established, and large clinical trials are lacking. We aimed to review the existing data regarding the treatment of actinic cheilitis with various modalities regarding safety, efficacy, recursions, and post-treatment malignant transformation. A systematic review was conducted through Pubmed, Ovid and the Cochrane library for studies in English language and the references of included papers from inception to January 2021. Case series were considered if ≥6 patients were included. Of the 698 articles, 36 studies and, overall, 699 patients were eventually reviewed. Laser ablation and vermilionectomy provided the best clinical and aesthetic outcomes with few recurrences, while photodynamic therapy was linked to more relapses. Generally, the adverse events were minor and there was no risk of post-treatment malignant transformation. The limitations of our review include the heterogeneity and the small number of patients across studies. Conclusively, invasive treatments demonstrated superior therapeutic and safety profile. Nevertheless, high-quality head-to-head studies that assess different modalities for actinic cheilitis and report patient preferences are lacking.
Collapse
|
3
|
Medeiros CKS, de França GM, Lima JGDC, Pinheiro JC, Almeida DRDMF, Santos PPDA. Use of topical anti-inflammatory and antineoplastic agents in the treatment of young-aged actinic cheilitis: A systematic review. J Cosmet Dermatol 2021; 21:473-481. [PMID: 33786961 DOI: 10.1111/jocd.14118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Revised: 03/12/2021] [Accepted: 03/23/2021] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Several treatments have been used to reduce inflammation and to reverse epithelial alterations in actinic cheilitis (AC). AIM A systematic review was conducted to analyze the potential of topical treatments for remission and clinical improvement of AC as well as patient acceptability. METHODS A systematic review of clinical trials was conducted following the PICO strategy to answer the following question: Are topical anti-inflammatory and antineoplastic agents effective in the treatment of actinic cheilitis? The quality of the studies was assessed by ROB-2, and the certainty of evidence was rated by GRADE guidelines. RESULTS Eight clinical trials were selected, including four that investigated the use of anti-inflammatory drugs and four use of antineoplastic agents. The use of 3% diclofenac sodium was associated with partial remission of AC, while 5% imiquimod and ingenol mebutate promoted complete remission. Furthermore, 5% fluorouracil was the drug most associated with complications during treatment. Diclofenac sodium (3%) and fludroxycortide showed the best acceptance by the patients, especially in terms of symptom relief and comfort provided. CONCLUSION The anti-inflammatory and antineoplastic agents analyzed largely provided good clinical outcomes, with evidence of remission of AC lesions, development of few local adverse reactions during treatment, and good patient adherence.
Collapse
Affiliation(s)
- Cristianne Kalinne Santos Medeiros
- Postgraduate Program in Dental Sciences, Area of Concentration in Stomatology and Oral Pathology, Federal University of Rio Grande do Norte, Natal, RN, Brazil
| | - Glória Maria de França
- Postgraduate Program in Dental Sciences, Area of Concentration in Stomatology and Oral Pathology, Federal University of Rio Grande do Norte, Natal, RN, Brazil
| | - Jabes Gennedyr da Cruz Lima
- Postgraduate Program in Dental Sciences, Area of Concentration in Stomatology and Oral Pathology, Federal University of Rio Grande do Norte, Natal, RN, Brazil
| | - Juliana Campos Pinheiro
- Postgraduate Program in Dental Sciences, Area of Concentration in Experimental Biology, Federal University of Rio Grande do Norte, Natal, RN, Brazil
| | | | - Pedro Paulo de Andrade Santos
- Postgraduate Program in Dental Sciences, Area of Concentration in Stomatology and Oral Pathology, Federal University of Rio Grande do Norte, Natal, RN, Brazil
| |
Collapse
|
4
|
Trager MH, Farmer K, Ulrich C, Basset-Seguin N, Herms F, Geskin LJ, Bouaziz JD, Lebbé C, de Masson A, Bagot M, Dobos G. Actinic cheilitis: a systematic review of treatment options. J Eur Acad Dermatol Venereol 2020; 35:815-823. [PMID: 33251620 DOI: 10.1111/jdv.16995] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Accepted: 10/02/2020] [Indexed: 12/20/2022]
Abstract
Actinic cheilitis is a premalignant condition that can progress to squamous cell carcinoma with a higher propensity for metastasis than cutaneous squamous cell carcinoma. Optimal treatment for actinic cheilitis has not been established, and evidence-based estimates of clinical cure in the dermatology literature are limited. Here, we review and synthesize outcome data published for patients with actinic cheilitis after treatment with various modalities. A systematic review was conducted in MEDLINE, Embase and the Cochrane library for English, French and German-language studies and references of included articles from inception to 20 January 2020. Studies were included if they reported on at least six patients with biopsy-proven actinic cheilitis. After quality appraisal, results of studies with the strongest methodology criteria were synthesized. 18 studies of 411 patients (published 1985 to 2016) were included. The majority of the studies were case series. Carbon dioxide laser ablation and vermilionectomy were associated with the most favourable outcomes with fewest recurrences. Chemical peel and photodynamic therapy were associated with higher recurrence. Adverse effects generally resolved in the weeks following treatment and cosmetic outcomes were favourable overall. In conclusion, there is a lack of high-quality comparative studies evaluating different treatment options for actinic cheilitis. The included publications used various outcome measures; however, the majority reported on the recently defined core outcome sets. These results suggest that both carbon dioxide laser ablation and vermilionectomy are effective treatments for actinic cheilitis. Prospective head-to-head studies are needed to compare these treatment modalities and to assess patient preferences.
Collapse
Affiliation(s)
- M H Trager
- Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA
| | - K Farmer
- Skin Cancer Centre, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - C Ulrich
- Skin Cancer Centre, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - N Basset-Seguin
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France.,U976, INSERM, Saint-Louis Hospital, Paris, France.,Université de Paris, Paris, France
| | - F Herms
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | - L J Geskin
- Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA
| | - J-D Bouaziz
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France.,U976, INSERM, Saint-Louis Hospital, Paris, France.,Université de Paris, Paris, France
| | - C Lebbé
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France.,U976, INSERM, Saint-Louis Hospital, Paris, France.,Université de Paris, Paris, France
| | - A de Masson
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France.,U976, INSERM, Saint-Louis Hospital, Paris, France.,Université de Paris, Paris, France
| | - M Bagot
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France.,U976, INSERM, Saint-Louis Hospital, Paris, France.,Université de Paris, Paris, France
| | - G Dobos
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France.,U976, INSERM, Saint-Louis Hospital, Paris, France.,Université de Paris, Paris, France
| |
Collapse
|